只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 2026-06-23 2026-06-25 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 1,450 | US$18.00 | US$26,100.00 | 51,776 | SEC |
| 2026-05-28 2026-06-01 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 679 | US$16.00 | US$10,864.00 | 47,122 | SEC |
| 2026-05-22 2026-05-26 | AVT AVNET INC | JACOBSON KENNETH A Officer · Chief Financial Officer | 卖出（S） | 12,000 | US$85.26 | US$102.31万 | 40,968 | SEC |
| 2026-05-15 2026-05-19 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 3,000 | US$18.76 | US$56,280.00 | 3,622 | SEC |
| 2026-05-08 2026-05-11 | AVTR Avantor, Inc. | LUCIER GREGORY T Director | 买入（P） | 10,000 | US$8.32 | US$83,200.00 | 60,000 | SEC |
| 2026-05-07 2026-05-11 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 18,606 | US$24.12 | US$448,776.72 | 423 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 37,375 | US$18.91 | US$706,761.25 | 41,322 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 5,196 | US$19.78 | US$102,776.88 | 36,126 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 9,253 | US$22.70 | US$210,043.10 | 4,034 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 400 | US$23.71 | US$9,484.00 | 3,634 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 22,839 | US$21.22 | US$484,643.58 | 13,287 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Chan Mitchell Director | 卖出（S） | 3,167 | US$22.88 | US$72,460.96 | 3,166 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 9,219 | US$21.37 | US$197,010.03 | 9,323 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 2,700 | US$20.76 | US$56,052.00 | 18,542 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 12,347 | US$19.28 | US$238,050.16 | 21,242 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 8,900 | US$22.57 | US$200,873.00 | 423 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 13,834 | US$18.55 | US$256,620.70 | 33,589 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 19,015 | US$22.41 | US$426,126.15 | 13,680 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 44,944 | US$21.20 | US$952,812.80 | 32,695 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 5,000 | US$19.65 | US$98,250.00 | 77,639 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 27,538 | US$18.03 | US$496,510.14 | 82,639 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 10,058 | US$22.88 | US$230,127.04 | 3,622 | SEC |
| 2026-05-05 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 1,679 | US$16.00 | US$26,864.00 | 3,622 | SEC |
| 2026-05-05 2026-05-06 | AVT AVNET INC | GALLAGHER PHILIP R Director,Officer · Chief Executive Officer | 卖出（S） | 23,920 | US$82.92 | US$198.34万 | 145,003 | SEC |
| 2026-05-01 2026-05-05 | AVTR Avantor, Inc. | Dingemans Simon Director | 买入（P） | 25,000 | US$8.14 | US$203,500.00 | 25,000 | SEC |
| 2026-04-30 2026-05-01 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 8,457 | US$13.23 | US$111,886.11 | 423 | SEC |
| 2026-04-29 2026-05-01 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 8,458 | US$13.09 | US$110,715.22 | 8,880 | SEC |
| 2026-04-06 2026-04-08 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 3,970 | US$18.01 | US$71,499.70 | 3,622 | SEC |
| 2026-04-02 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 1,780 | US$17.57 | US$31,274.60 | 17,338 | SEC |
| 2026-04-02 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 6,200 | US$17.02 | US$105,524.00 | 19,118 | SEC |
| 2026-04-01 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 7,479 | US$16.83 | US$125,871.57 | 25,318 | SEC |
| 2026-04-01 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 500 | US$15.86 | US$7,930.00 | 32,797 | SEC |
| 2026-04-01 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 679 | US$16.00 | US$10,864.00 | 3,622 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| AVTX | 220,489.4207 | 0 | 325,177.6768 | 67.81% | B, Q, N |
| AVT | 283,902.5193 | 924 | 436,365.87 | 65.06% | B, Q, N |
| AVTR | 1,951,163.3667 | 2,709 | 4,576,771.3814 | 42.63% | B, Q, N |
| AVTM | 3.0186 | 0 | 8.533 | 35.38% | Q |